Association of Genetic Variants With Myopia

Sponsor
Beijing Visionly Plus Eye Hospital
Study ID
NCT07030153
Status
Recruiting
Apply to this trial

Conditions

  • Myopia

Eligibility Criteria

Sex
ALL
Age
6 Years - 18 Years
Healthy Volunteers
Accepted

Interventions

  • Oral swab DNA analyzed for myopia-related gene variants — GENETIC
    Beyond detecting links between gene variants and myopia development, the testing analyzes how these variants influence treatment effectiveness. The aim is to enable early risk prediction and personalized treatment guidance for children through oral DNA testing.

Study Details

This study aims to identify genetic factors linked to myopia, including those that influence a person's risk of developing it and how quickly it progresses (like changes in eye length). It will also examine how different treatments-such as low-dose atropine drops, orthokeratology lenses, specialized glasses, and increased outdoor time-interact with these genes. Finally, the research will develop a genetic risk score to help tailor personalized myopia prevention and treatment plans.

Key Dates

First listed
Jun 22, 2025
Start date
Jul 1, 2025
Status verified
Jun 2025
Primary completion
Aug 31, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
1,000 participants (estimated)

Arms

  • Arm: Genetic and myopia onset
    Identify genetic variants (GWAS/WES) associated with: * Myopia onset risk (high-risk SNPs ). * Myopia progression rate (e.g., axial elongation/year).
  • Arm: Genetic and myopia intervention
    Evaluate gene-intervention interactions for: * Low-dose atropine (0.01%, 0.05%). * Orthokeratology. * Defocus-incorporated spectacles. * Outdoor/sunlight exposure (≥2 hours/day).

Primary Outcome Measure

Polygenic Risk Score (PRS) for Myopia Progression [ Time Frame: Every 6 months for 3 years ]

Central Contacts

Related Studies